Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MCS002
MIFTS: 56

Mucositis

Categories: Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mucositis

About this section

MalaCards integrated aliases for Mucositis:

Name: Mucositis 12 54 43 15 17
Inflammatory Disease of Mucous Membrane 71
Gastrointestinal Mucositis 71

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080178
MeSH 43 D052016
UMLS 71 C0333355 C0521585
Sources

Summaries for Mucositis

About this section
Disease Ontology : 12 A gastrointestinal system disease that is characterized by painful inflammation and ulceration of the mucous membranes lining the digestive tract.

MalaCards based summary : Mucositis, also known as inflammatory disease of mucous membrane, is related to peptic ulcer disease and esophagitis, and has symptoms including signs and symptoms, digestive, oral manifestations and catarrh. An important gene associated with Mucositis is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Posaconazole and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and bone marrow, and related phenotypes are growth/size/body region and behavior/neurological

Wikipedia : 74 Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract,... more...

Sources

Related Diseases for Mucositis

About this section

Diseases related to Mucositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1757)
# Related Disease Score Top Affiliating Genes
1 peptic ulcer disease 32.9 IL1B IL10 GHRL
2 esophagitis 32.9 VEGFA IL1B IL10 EGF
3 cyclic neutropenia 32.8 IL1B CSF3 CSF2
4 colitis 32.1 IL2 IL1B IL10 ABCB1
5 squamous cell carcinoma, head and neck 32.0 VEGFA TYMS HGF EGF DPYD CSF2
6 ulcerative colitis 32.0 IL2 IL1B IL10 ABCB1
7 crohn's disease 31.9 IL2 IL1B IL10 ABCB1
8 gastric ulcer 31.7 VEGFA IL1B HGF EGF
9 duodenal ulcer 31.7 IL1B IL10 EGF
10 candidiasis 31.7 IL2 IL1B IL10 CSF2
11 diarrhea 31.5 IL2 IL1B IL10 HTR3A CSF3 ABCB1
12 irritable bowel syndrome 31.5 IL1B IL10 HTR3A GHRL
13 otitis media 31.5 IL2 IL1B IL10 CSF3
14 celiac disease 1 31.4 IL2 IL1B IL10 GHRL
15 tetanus 31.4 IL2 IL1B IL10 CSF2
16 graft-versus-host disease 31.4 IL2 IL1B IL10
17 aphthous stomatitis 31.3 IL2 IL1B IL10 CSF2
18 atrophic gastritis 31.3 IL1B IL11 IL10 GHRL EGF
19 bacterial infectious disease 31.3 IL1B IL10 CSF3 CSF2
20 gastroenteritis 31.3 IL1B IL10 CSF3 CSF2
21 perinatal necrotizing enterocolitis 31.3 IL1B IL10 EGF
22 cutaneous leishmaniasis 31.3 IL2 IL1B IL10
23 chlamydia 31.2 IL1B IL10 CSF2
24 gingivitis 31.1 IL2 IL1B IL10 CSF3
25 acute graft versus host disease 31.1 IL2 IL10 CSF3
26 diphtheria 31.1 IL2 IL1B EGF CSF2
27 acquired immunodeficiency syndrome 31.1 IL2 IL1B IL10 CSF2
28 short bowel syndrome 31.0 HGF GHRL FGF7 EGF
29 contact dermatitis 30.9 IL2 IL1B IL10
30 severe combined immunodeficiency 30.9 VEGFA IL2 IL10 CSF3 CSF2
31 appendicitis 30.8 IL2 IL1B IL10 CSF3
32 leprosy 3 30.8 IL2 IL1B IL10 CSF2
33 vaginitis 30.8 IL1B IL10 ABCB1
34 ileus 30.8 IL1B IL10 GHRL CSF2
35 visceral leishmaniasis 30.8 IL2 IL1B IL10
36 common cold 30.7 IL1B IL10 CSF2
37 bacterial pneumonia 30.7 IL1B IL10 CSF3
38 sleep apnea 30.7 VEGFA IL1B IL10 GHRL
39 coccidiosis 30.6 IL2 IL1B IL10
40 lung disease 30.6 VEGFA IL1B IL10 FGF7 CSF3 CSF2
41 intestinal obstruction 30.6 VEGFA MTOR GHRL
42 tonsillitis 30.6 IL2 IL1B IL10
43 aspergillosis 30.6 IL1B IL10 CSF3 CSF2
44 exanthem 30.6 VEGFA MTOR IL2 IL1B IL10 CSF3
45 autoimmune gastritis 30.6 IL2 IL1B IL10 EGF
46 viral hepatitis 30.6 IL2 IL1B IL10 HGF
47 leukemia, acute lymphoblastic 30.6 TYMS MTHFR IL2 CSF3 CSF2 ABCB1
48 rectal disease 30.6 IL2 IL1B IL10
49 osteonecrosis 30.5 VEGFA MTHFR IL1B IL10 ABCB1
50 acute leukemia 30.5 MTHFR IL2 CSF3 CSF2 ABCB1

Graphical network of the top 20 diseases related to Mucositis:



Diseases related to Mucositis
Sources

Symptoms & Phenotypes for Mucositis

About this section

UMLS symptoms related to Mucositis:


signs and symptoms, digestive, oral manifestations, catarrh

MGI Mouse Phenotypes related to Mucositis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.28 ABCB1 CSF2 EGF FGF7 HGF HTR3A
2 behavior/neurological MP:0005386 10.27 ABCB1 CSF2 DPYD FGF7 GHRL HTR3A
3 hematopoietic system MP:0005397 10.22 ABCB1 CSF2 CSF3 FGF7 HGF HTR3A
4 homeostasis/metabolism MP:0005376 10.18 ABCB1 CSF2 FGF7 GHRL HTR3A IL10
5 endocrine/exocrine gland MP:0005379 10.16 ABCB1 CSF2 EGF GHRL HTR3A IL10
6 immune system MP:0005387 10.13 ABCB1 CSF2 CSF3 EGF FGF7 HTR3A
7 digestive/alimentary MP:0005381 10.08 ABCB1 DPYD EGF GHRL IL10 IL2
8 integument MP:0010771 9.96 CSF2 CSF3 EGF FGF20 FGF7 HTR3A
9 nervous system MP:0003631 9.9 ABCB1 CSF2 FGF20 FGF7 HTR3A IL10
10 no phenotypic analysis MP:0003012 9.5 ABCB1 HGF IL10 IL2 MTHFR MTOR
11 reproductive system MP:0005389 9.36 ABCB1 CSF2 DPYD EGF FGF7 HTR3A
Sources

Drugs & Therapeutics for Mucositis

About this section

Drugs for Mucositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 461)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
2
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
3
Ethanol Approved Phase 4 64-17-5 702
4
Metronidazole Approved Phase 4 443-48-1 4173
5
Hexetidine Approved, Investigational Phase 4 141-94-6
6
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
7
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
8
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
9
Ifosfamide Approved Phase 4 3778-73-2 3690
10
Gemcitabine Approved Phase 4 95058-81-4 60750
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13
Methylene blue Approved, Investigational Phase 4 61-73-4
14
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
15
Fluorouracil Approved Phase 4 51-21-8 3385
16
Promethazine Approved, Investigational Phase 4 60-87-7 4927
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
19
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
20
Povidone Approved Phase 4 9003-39-8
21
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
22
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
23
Simethicone Approved Phase 4 8050-81-5
24
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
25
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
26
Erythritol Experimental Phase 4 149-32-6, 2418-52-2 169019
27 Anti-Infective Agents, Local Phase 4
28 Hypnotics and Sedatives Phase 4
29 Cytochrome P-450 Enzyme Inhibitors Phase 4
30 Disinfectants Phase 4
31 Chlorhexidine gluconate Phase 4
32 Cytochrome P-450 CYP3A Inhibitors Phase 4
33 Cola Phase 4
34 Vasodilator Agents Phase 4
35 Ether Phase 4
36
Hydroxyitraconazole Phase 4
37 Laxatives Phase 4
38 Cathartics Phase 4
39 Picosulfate sodium Phase 4
40 Gastrointestinal Agents Phase 4
41 Antiemetics Phase 4
42 Antiviral Agents Phase 4
43
Isophosphamide mustard Phase 4 0
44
asparaginase Phase 4
45 Antimetabolites Phase 4
46 Protective Agents Phase 4
47 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
48 Adjuvants, Immunologic Phase 4
49 Plasma Substitutes Phase 4
50 Blood Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 573)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
2 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
3 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
4 Clinical and Microbiological Evaluation of the Effect of Probiotic Lactobacillus Reuteri Prodentis in the Treatment of Mucositis and Periimplantitis Completed NCT03047291 Phase 4 Probiotic
5 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
6 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
7 Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer Completed NCT00333099 Phase 4
8 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
9 The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Peri-implant Mucositis and Peri-implantitis. Completed NCT02023853 Phase 4 metronidazole gel
10 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
11 A Pilot Randomised Comparison of Bicarbonate Based Mouth Care Versus Biotene Based Mouth Care During Radiotherapy Completed NCT00138827 Phase 4 Biotene (mouth care)
12 Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash;Placebo
13 Impact of Oral Hygiene Gels on Peri-implant Mucositis Completed NCT03243591 Phase 4
14 Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
15 Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
16 A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
17 Effect of Eszopiclone (Lunesta) on Sleep Disturbance and Pain in Cancer Completed NCT00365261 Phase 4 Eszopiclone;Placebo
18 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
20 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
21 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin injection;Compound kushen injection
22 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
23 A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
24 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Not yet recruiting NCT04292990 Phase 4 Fentanyl;Morphine
25 Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical Treatment of Peri-implant Disease Not yet recruiting NCT04187053 Phase 4 Saline;Methylene Blue
26 Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity Not yet recruiting NCT04269369 Phase 4 5-Fluorouracil
27 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
28 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
29 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
30 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
31 Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial Unknown status NCT02313792 Phase 3 Palifermin
32 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
33 Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults Unknown status NCT02173756 Phase 3 morphine gel;placebo gel
34 Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1" Unknown status NCT01007617 Phase 2, Phase 3
35 The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial Unknown status NCT02282839 Phase 3
36 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
37 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
38 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
39 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Unknown status NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
40 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
41 the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial Unknown status NCT00603759 Phase 3 celecoxib;placebo
42 Regenerative Treatment of Peri-Implantitis: Double Blind Randomized Controlled Clinical Trial Unknown status NCT02575274 Phase 2, Phase 3
43 Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation. Unknown status NCT01955772 Phase 3 Enteral nutrition alanyl-glutamin, Dipeptiven
44 Efficacy and Cost Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Locally Advanced Head and Neck Cancer to Prevent Aspiration Pneumonia. A Randomized Phase II-III Study Unknown status NCT01598402 Phase 2, Phase 3 amoxicillin/clavulanic acid suspension
45 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
46 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 To Access the Effects of Mucositis in Adults With Dental Implants Completed NCT01072201 Phase 3 Triclosan and Fluoride;Fluoride
48 Effect of Low-level Laser Therapy on Inflammatory Mediators Release During Chemotherapy-induced Oral Mucositis: a Randomized Preliminary Study Completed NCT02050373 Phase 3
49 Serial Controlled N-of-1 Trials of Topical Vitamin E as Prophylaxis for Chemotherapy-induced Oral Mucositis in Pediatric Patients Completed NCT00311116 Phase 2, Phase 3 Vitamin E
50 Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan Completed NCT01837446 Phase 2, Phase 3 2% morphine solution;Magnesium aluminum hydroxide;2% viscous lidocaine;Diphenhydramine

Search NIH Clinical Center for Mucositis

Cochrane evidence based reviews: mucositis

Sources

Genetic Tests for Mucositis

About this section
Sources

Anatomical Context for Mucositis

About this section

MalaCards organs/tissues related to Mucositis:

40
Breast, Bone, Bone Marrow, Lung, Myeloid, Colon, T Cells
Sources

Publications for Mucositis

About this section

Articles related to Mucositis:

(show top 50) (show all 9610)
# Title Authors PMID Year
1
The use of GLP-2 and related growth factors in intestinal diseases. 61 54
20336592 2010
2
Keratinocyte growth factor. 54 61
19456212 2009
3
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. 61 54
18829546 2008
4
Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. 54 61
18197435 2008
5
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. 61 54
18560408 2008
6
Cytokines following SCT: indications and controversies. 54 61
18545239 2008
7
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. 54 61
18299612 2008
8
DPYD*2A mutation: the most common mutation associated with DPD deficiency. 61 54
17165084 2007
9
The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature. 61 54
18632516 2007
10
Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. 54 61
17728847 2007
11
Interventions for treating oral mucositis for patients with cancer receiving treatment. 54 61
17443514 2007
12
Head and neck radiation and mucositis. 54 61
18660721 2007
13
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. 61 54
17293228 2007
14
Cancer treatment-induced oral mucositis. 54 61
17465250 2007
15
Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. 54 61
17059384 2006
16
A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. 61 54
16904525 2006
17
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. 61 54
16965690 2006
18
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. 61 54
16912178 2006
19
Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy. 54 61
16634706 2006
20
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. 54 61
16803675 2006
21
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. 61 54
16414253 2006
22
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. 61 54
16537186 2006
23
R-Spondin proteins: a novel link to beta-catenin activation. 61 54
16357527 2006
24
The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments. 61 54
16322806 2005
25
Mucosal protection by cytokines. 54 61
16232381 2005
26
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. 54 61
15683818 2005
27
Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. 54 61
16110136 2005
28
Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. 61 54
15623608 2004
29
Interventions for treating oral mucositis for patients with cancer receiving treatment. 54 61
15106165 2004
30
Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. 61 54
12649101 2003
31
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. 54 61
12697866 2003
32
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. 54 61
12759532 2003
33
Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. 61 54
12243825 2002
34
The effects of keratinocyte growth factor in preclinical models of mucositis. 54 61
12139710 2002
35
Are Central Eastern European countries involved in clinical trials of supportive care? 61 54
12029429 2002
36
A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. 61 54
11919725 2002
37
Biological actions and therapeutic potential of the glucagon-like peptides. 61 54
11832466 2002
38
Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. 54 61
11597377 2001
39
Genomics and drug discovery. 54 61
11511852 2001
40
Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. 54 61
11545238 2001
41
Comment on: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 54 61
11503611 2001
42
Repifermin. Human Genome Sciences/GlaxoSmithKline. 61 54
15995938 2001
43
Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. 54 61
11313683 2001
44
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. 61 54
11212269 2001
45
Prevention and management of mucositis in patients with cancer. 54 61
11053801 2000
46
Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. 61 54
10899677 2000
47
Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 61 54
10701730 2000
48
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. 54 61
10578158 1999
49
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. 61 54
10473079 1999
50
Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. 54 61
10389920 1999
Sources

Variations for Mucositis

About this section
Sources

Expression for Mucositis

About this section
Search GEO for disease gene expression data for Mucositis.
Sources

Pathways for Mucositis

About this section

Pathways related to Mucositis according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.04 VEGFA MTOR IL2 IL1B IL11 IL10
2
ERK Signaling 63
Show member pathways
 13.74 VEGFA TGFB3 MTOR IL2 IL1B IL11
3
PEDF Induced Signaling 63
Show member pathways
 13.69 TGFB3 MTOR IL2 IL1B IL11 IL10
4
TGF-Beta Pathway 63
Show member pathways
 13.51 VEGFA TGFB3 MTOR IL2 IL1B IL11
5
CREB Pathway 63
Show member pathways
 13.33 TGFB3 IL2 HTR3A HGF FGF7 FGF20
6
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.28 VEGFA TGFB3 IL2 HGF FGF7 FGF20
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.28 VEGFA IL2 IL1B IL11 IL10 HGF
8
Akt Signaling 63
Show member pathways
 13.18 TGFB3 MTOR IL2 IL1B IL11 IL10
9
PAK Pathway 63
Show member pathways
 13.13 TGFB3 IL2 IL1B IL11 IL10 HGF
10
Phospholipase-C Pathway 63
Show member pathways
 13.09 TGFB3 MTOR IL2 HGF FGF7 FGF20
11
p70S6K Signaling 63
Show member pathways
 13.07 TGFB3 MTOR IL2 HGF FGF7 FGF20
12
PI3K-Akt signaling pathway 36
Show member pathways
 13 VEGFA MTOR IL2 HGF FGF7 FGF20
13
Allograft rejection 1 36
Show member pathways
 12.85 VEGFA IL2 IL1B IL10 ABCB1
14
MAPK signaling pathway 36 1
12.8 VEGFA TGFB3 IL1B HGF FGF7 FGF20
15
Pathways in cancer 36
12.8 VEGFA TGFB3 MTOR IL2 HGF FGF7
16
Gastric cancer 36
Show member pathways
 12.79 TGFB3 MTOR HGF FGF7 FGF20 EGF
17
Ras signaling pathway 36
Show member pathways
 12.74 VEGFA HGF FGF7 FGF20 EGF
18
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.73 MTOR HGF FGF7 FGF20 EGF
19
NF-KappaB Family Pathway 63
Show member pathways
 12.71 TGFB3 IL2 IL1B HGF FGF7 FGF20
20
Glioma 36
Show member pathways
 12.68 MTOR HGF FGF7 FGF20 EGF
21
T cell receptor signaling pathway 36
Show member pathways
 12.65 MTOR IL2 IL1B IL10 EGF CSF2
22
ErbB signaling pathway 36 1
Show member pathways
 12.63 VEGFA TGFB3 MTOR HGF EGF
23
Th17 cell differentiation 36
Show member pathways
 12.61 TGFB3 MTOR IL2 IL1B IL10
24
JAK-STAT signaling pathway 36
Show member pathways
 12.45 MTOR IL2 IL11 IL10 EGF CSF3
25
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.44 TGFB3 MTOR IL2 HGF FGF7 FGF20
26
RhoGDI Pathway 63
Show member pathways
 12.39 VEGFA FGF7 FGF20 EGF
27
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.25 TGFB3 IL2 IL1B IL10 HGF FGF7
28
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.19 VEGFA IL1B IL10 HTR3A
29
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
12.13 VEGFA IL11 HGF FGF7 EGF
30
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.04 IL2 IL11 IL10 CSF3 CSF2
31
Interleukin-4 and 13 signaling 65
12.01 VEGFA IL1B IL10 HGF
32
Amoebiasis 36
11.96 TGFB3 IL1B IL10 CSF2
33
Hematopoietic cell lineage 36
11.93 IL1B IL11 CSF3 CSF2
34
Rheumatoid arthritis 36
11.89 VEGFA TGFB3 IL1B IL11 CSF2
35
Dendritic Cells Developmental Lineage Pathway 64
11.8 IL2 IL1B IL10 CSF2
36
Innate Lymphoid Cells Differentiation 64
11.79 IL2 IL1B IL10
37
G-protein signaling_RhoA regulation pathway 22
11.78 TGFB3 IL2 HGF FGF7 FGF20 EGF
38
Fluoropyrimidine Activity 1
Show member pathways
 11.76 TYMS MTHFR DPYD
39
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.72 VEGFA IL2 IL1B CSF2
40
Regulation of Telomerase 1
11.7 MTOR IL2 EGF
41
Interleukin-10 signaling 65
11.6 IL1B IL10 CSF3 CSF2
42
Hematopoietic Stem Cell Differentiation 1
11.54 IL1B CSF3 CSF2
43
Malaria 36
11.5 TGFB3 IL1B IL10 HGF CSF3
44
Vemurafenib Pathway, Pharmacodynamics 60
11.48 VEGFA FGF7 EGF
45
Signaling events mediated by TCPTP 1
Show member pathways
 11.47 VEGFA HGF EGF
46
Differentiation Pathway 1
11.45 VEGFA TGFB3 IL11 HGF EGF
47
Lung fibrosis 1
11.43 IL1B HGF FGF7 EGF CSF3 CSF2
48
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.42 TGFB3 IL2 IL10 CSF2
49
Antifolate resistance 36
11.33 TYMS MTHFR IL1B
50
Extracellular vesicle-mediated signaling in recipient cells 1
11.31 TGFB3 MTOR HGF
Sources

GO Terms for Mucositis

About this section

Cellular components related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 VEGFA TGFB3 IL2 IL1B IL11 IL10
2 extracellular region GO:0005576 9.47 VEGFA TGFB3 RSPO1 IL2 IL1B IL11
3 platelet alpha granule lumen GO:0031093 9.46 VEGFA TGFB3 HGF EGF

Biological processes related to Mucositis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.2 VEGFA TGFB3 IL1B IL11 IL10 HTR3A
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 VEGFA TGFB3 IL2 IL1B IL11 IL10
3 immune response GO:0006955 10.04 IL2 IL1B IL10 CSF3 CSF2
4 positive regulation of gene expression GO:0010628 10.03 VEGFA MTOR IL1B EGF CSF2
5 positive regulation of cell migration GO:0030335 9.95 VEGFA IL1B HGF EGF
6 cellular response to lipopolysaccharide GO:0071222 9.9 IL1B IL10 CSF3 CSF2
7 positive regulation of protein phosphorylation GO:0001934 9.85 VEGFA RSPO1 MTOR IL2 IL1B HGF
8 negative regulation of inflammatory response GO:0050728 9.84 IL2 IL10 HGF GHRL
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 VEGFA IL11 CSF3
10 platelet degranulation GO:0002576 9.83 VEGFA TGFB3 HGF EGF
11 response to ethanol GO:0045471 9.81 TYMS IL2 HTR3A CSF3
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 VEGFA IL2 CSF2
13 activation of MAPK activity GO:0000187 9.8 TGFB3 IL1B HGF GHRL EGF
14 positive regulation of protein kinase B signaling GO:0051897 9.8 MTOR HGF FGF7 FGF20 EGF CSF3
15 MAPK cascade GO:0000165 9.8 IL2 IL1B HGF FGF7 FGF20 EGF
16 positive regulation of endothelial cell proliferation GO:0001938 9.79 VEGFA MTOR IL10
17 negative regulation of autophagy GO:0010507 9.77 MTOR IL10 HGF
18 positive chemotaxis GO:0050918 9.76 VEGFA HGF FGF7
19 cytokine-mediated signaling pathway GO:0019221 9.76 VEGFA IL2 IL1B IL11 IL10 HGF
20 positive regulation of epithelial to mesenchymal transition GO:0010718 9.75 TGFB3 MTOR IL1B
21 positive regulation of cell division GO:0051781 9.73 VEGFA TGFB3 IL1B FGF7
22 positive regulation of sprouting angiogenesis GO:1903672 9.67 VEGFA IL10 GHRL
23 positive regulation of keratinocyte migration GO:0051549 9.65 MTOR FGF7
24 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.65 IL10 GHRL
25 positive regulation of cell proliferation GO:0008284 9.65 VEGFA TGFB3 IL2 IL1B IL11 FGF7
26 tetrahydrofolate interconversion GO:0035999 9.64 TYMS MTHFR
27 tetrahydrofolate metabolic process GO:0046653 9.63 TYMS MTHFR
28 response to folic acid GO:0051593 9.61 TYMS MTHFR
29 regulation of complement-dependent cytotoxicity GO:1903659 9.61 IL11 IL10
30 positive regulation of eating behavior GO:1904000 9.57 MTOR GHRL
31 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.56 HGF FGF7
32 regulation of response to food GO:0032095 9.55 MTOR GHRL
33 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.17 VEGFA MTOR IL11 HGF FGF7 EGF

Molecular functions related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 VEGFA TGFB3 IL2 IL1B IL11 IL10
2 growth factor activity GO:0008083 9.36 VEGFA TGFB3 IL2 IL11 IL10 HGF
3 chemoattractant activity GO:0042056 9.33 VEGFA HGF FGF7
Sources

Sources for Mucositis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....